Mesenbio secures £1.4million in funding. Together with grant funding from Innovate UK, DSW Ventures and NG Bio co-led the round.
With the help of the funds, the company will be able to conduct pre-clinical research, build pilot manufacturing processes, hire three new employees, and get the regulatory dossier ready for clinical trials.
Mesenbio, founded by Dr. David Kuntin and Professor Paul Genever, is developing an innovative therapy for arthritis made from modified human stem cells. The medicine is based on their work at the Biomedical Research Institute at the University of York.
The inflammatory illness that affects almost half a million people and children in the UK alone, rheumatoid arthritis, will be the primary focus of the treatment. It causes excruciating joint pain and inflammation in the hands, knees, elbows, ankles, and wrists.
The therapy is based on nano-sized messengers made from human stem cells that have been developed to both reduce inflammation and stimulate the healing process of injured tissue.
A biopharmaceutical startup from the University of York, Mesenbio is in the preclinical stage. Their Cell Line Extracellular Vesicle Release (CLEVR) platform addresses the most common hurdle in extracellular vesicle therapeutics consistency, allowing us to pursue a diverse therapeutic pipeline. They utilise their platform to generate therapeutically stimulating extracellular vesicles in an infinitely dependable manner.